Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Heartware International Shares Are Crashing Today

By Todd Campbell - Oct 13, 2015 at 2:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Heartware International is researching adverse events in patients participating in trials of its next-generation heart device.

Source: Heartware International

What: After reporting that it is investigating the cause of adverse events in patients participating in a trial of its next-generation heart pump, shares in Heartware International (NASDAQ: HTWR) tumbled by over 18% earlier today.

So what: Heartware International manufactures implantable pumps that can take over some or all of the heart's pumping function.

The company's ventricular assist devices (HVAD) are used as either a bridge to transplantation or instead of transplantation, but they're still bigger than the company (and surgeons) would like, and the invasiveness associated with the surgical procedure of implantation limits the number of people who can receive them.

As a result, Heartware is developing a next-generation pump -- the MVAD -- that is one-third the size of its HVAD's.

In September, Heartware reported that it had paused its MVAD trial to address a manufacturing issue and to update the MVAD software, and it appears that during discussions with trial investigators, the company became aware of adverse events in certain patients that, while not uncommon for patients receiving ventricular assist devices, warrant additional research.

Now what: Previously, Heartware had hoped to restart its MVAD trial in November; however, today's revelation casts doubt on that timeline. Instead, investors will have to wait and hope that the company offers up a new timeline for its MVAD trial when it reports third quarter earnings on October 29.

Until we learn what the adverse events were and get insight into when the MVAD trial can restart, investors are left with more questions than answers. Since Heartware is an unprofitable company, investors might be best served patiently waiting on the sidelines for insight, rather than jumping in and buying on this slide.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/05/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.